The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.

A method comprising executing a prescription digital therapeutic configured to treat symptoms associated with migraines experienced by a patient. Executing the prescription digital therapeutic comprises: (a) obtaining, by data processing hardware, a plurality of data from (i) first sensors associated with a patient electronic device, (ii) the patient via the patient electronic device, and (iii) a remote server; (b) weighting, by the data processing hardware, the plurality of data to provide a plurality of weighted data; (c) generating, by the data processing hardware, a migraine forecast prediction for the patient based on the plurality of weighted data; (d) determining, by the data processing hardware, a recommended dosage of a migraine-treating medication for the patient based on the migraine forecast prediction, the migraine-treating medication including one of a triptan or a calcitonin gene-related peptide (CGRP) inhibitor; and (e) instructing, by the data processing hardware, an administration unit to administer an administration dosage of the migraine-treating medication to the patient based on the recommended dosage.

Provided herein are, inter alia, methods and compositions for reducing and/or preventing ocular endothelial cell loss, and for treatment and/or prevention of ocular diseases.

Provided herein are, inter alia, methods and compositions for reducing and/or preventing ocular endothelial cell loss, and for treatment and/or prevention of ocular diseases.

A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one CGRP antagonist compound in a pharmaceutically acceptable formulation.

Methods for treating headache, migraine and related symptoms by administering a CGRP antagonist and a Clostridial derivative are described.

A calcitonin gene-related peptide (CGRP) compound can be selected from N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)-butyrylamino]ethoxy}ethoxy)acetyl][Ser1]alpha-human CGRP peptide (-CGRP-analogue), or derivatives thereof; or N-alpha-[2-(2-{2-[(S)-4-carboxy-4-(17-carboxyheptadecanoylamino)butyryl-amino]-ethoxy}ethoxy)acetyl][Ser1]beta-human CGRP peptide (-CGRP-analogue), or derivatives thereof. The CGRP compound can be used to induce myocardial perfusion recovery, in connection with AMI, by activating any CGRP family of receptors with a larger CGRP compound: CGRP potency ratio in the coronary artery than in the mesenteric artery.

Described herein are methods for treating a subject having or at risk of developing cancer administering a neuromodulating agent.

The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.